Neuland Laboratories Reports Q2FY26 Total Income at Rs.516.1 Crore, EBITDA at Rs.156.9 Crore

Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the half year ended Sep 30, 2025. The company reported a record high revenue driven by CMS commercial projects, leading to improved EBITDA margins. The momentum is expected to continue through the rest of the year. Customer interest in Neuland’s capabilities continues to rise, with increased engagement from a diverse range of customers and greater share of business from existing customers. The company's investments are helping to further differentiate Neuland as a partner of choice.